ModerateSNRI×Angiotensin II receptor blockers (sartans)
Updated · Methodology
Mechanism
Losartan lowers blood pressure by blocking angiotensin II receptors. Substances that can cause hypotension as an adverse effect, such as tricyclic antidepressants and antipsychotics, may increase the risk of hypotension (losartan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Duloxetine itself can cause orthostatic hypotension, syncope and falls. The risk of blood pressure decreases may be greater in patients taking drugs that induce orthostatic hypotension, such as antihypertensives (duloxetine prescribing information, US Food and Drug Administration, FDA). At the same time, through its noradrenergic effect, duloxetine raises blood pressure in some people, especially with pre-existing hypertension (duloxetine SmPC, European Medicines Agency, EMA). There is no shared pharmacokinetic pathway: CYP2C9 and CYP3A4 metabolise losartan, and duloxetine does not inhibit these enzymes (Cozaar and duloxetine prescribing information, FDA).
Symptoms
The documents describe no symptoms linked to this combination. A fall in blood pressure shows as dizziness, weakness or fainting on standing and falls, more often in the first week of duloxetine and after dose increases (duloxetine prescribing information, US Food and Drug Administration, FDA). The opposite effect is a sustained rise in blood pressure, up to a hypertensive crisis, more often in people with pre-existing hypertension (duloxetine SmPC, European Medicines Agency, EMA). Losartan itself can cause symptomatic hypotension in volume or sodium depletion, raised potassium and worsening renal function (losartan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is not contraindicated and is managed with blood pressure monitoring. Measure blood pressure before starting duloxetine and periodically during treatment (duloxetine prescribing information, US Food and Drug Administration, FDA). In people with hypertension, monitor it closely, especially during the first month (duloxetine SmPC, European Medicines Agency, EMA). Do not start duloxetine in uncontrolled hypertension (duloxetine SmPC, EMA). If blood pressure rises persistently, consider reducing the duloxetine dose or tapering it off (EMA). With symptomatic orthostatic hypotension, falls or syncope, consider dose reduction or discontinuation (FDA). Correct volume or sodium depletion from diuretics, diarrhoea or vomiting before starting losartan, or start losartan at a lower dose (losartan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During losartan treatment, monitor renal function regularly (losartan SmPC, AEMPS) and check potassium periodically (Cozaar prescribing information, FDA). Do not use duloxetine with creatinine clearance below 30 mL/min (duloxetine SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Losartan (nº registro 67729), sección 4.5 (2025)– AEMPS, CIMA, nº registro 67729, revisión 03/2025, sección 4.5
- FDA: Cozaar (losartan potassium) prescribing information (2026)– FDA, DailyMed setid 9949448f-c3b9-44ee-94ed-c1aca8c90f39 (Organon LLC), revised 01/2026, section 7
- AEMPS: Ficha técnica: Losartan (nº registro 67729), sección 4.4 (2025)– AEMPS, CIMA, nº registro 67729, revisión 03/2025, sección 4.4
- EMA: Ficha técnica: Duloxetina, Cymbalta (EU/1/04/296), sección 4.4 (2024)– EMA, ficha técnica Cymbalta, EU/1/04/296 (CIMA nregistro 04296001), texto publicado por la EMA, PDF de 05/2024, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Duloxetine delayed-release capsules (duloxetine) prescribing information (2026)– FDA, DailyMed, Lupin Pharmaceuticals, setid 829a4f51-c882-4b64-81f3-abfb03a52ebe, revised 05/2026, sections 4, 5.2, 5.4, 5.5, 7.1–7.17 and 12.2